Pharmanovia Collaborates with Radius Health to Commercialize Abaloparatide for Osteoporosis Treatment

Shots:

• Pharmanovia has signed an exclusive in-licensing agreement with Radius Health for abaloparatide (US brand name: Tymlos) to treat osteoporosis, expanding its osteoporosis franchise
• Pharmanovia will handle clinical, regulatory & commercial responsibilities across APAC region (China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau & Philippines), while Radius will get an upfront, regulatory & commercial milestones as well as net-sales-based tiered royalties
• Abaloparatide is a human PTH hormone related peptide analogue approved for postmenopausal women & men with osteoporosis at high fracture risk or those intolerant to other therapies, helping increase bone density

Ref: Pharmanovia | Image: Pharmanovia & Radius

Related News:- Pharmanovia Collaborates with Lindis Biotech to Commercialize Catumaxomab for Treating Malignant Ascites

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com